| Income Statement | 2025-10-31 | 2025-07-31 | 2024-10-31 | 2024-07-31 |
|---|---|---|---|---|
| Legal and professional | - | - | 469,685 | 510,556 |
| Director fees | - | - | 138,000 | 138,000 |
| Compensation expense | - | - | 283,333 | 389,484 |
| Revenue | 0 | 0 | - | - |
| Research and development costs | 141,085 | 95,157 | 97,470 | 96,016 |
| General and administrative | 1,234,966 | 753,148 | 117,572 | 134,831 |
| Total operating expenses | 1,376,051 | 848,305 | 1,106,060 | 1,268,887 |
| Loss from operations | -1,376,051 | -848,305 | -1,106,060 | -1,268,887 |
| Change in fair value of the derivative liability | - | - | - | 1,204,000 |
| Interest income | 206,387 | 217,793 | 382,562 | 547,432 |
| Change in fair value of warrant liability | -10,474,000 | 243,000 | 1,829,000 | 2,084,000 |
| Gain on related party investment - tnf | - | 0 | - | 21,395,734 |
| Change in fair value of derivative liability | 302,000 | 0 | 980,000 | - |
| Change in fair value of investment - tnf | - | -2,839,000 | -4,265,000 | 724,266 |
| Change in fair value of convertible note receivable - femasys | 392,000 | 912,000 | 435,000 | 245,000 |
| Change in fair value of warrant asset - femasys | -726,000 | -1,215,000 | 276,000 | -1,510,000 |
| Change in fair value of investment - qcls | -2,371,000 | - | - | - |
| Change in fair value of warrants - tnf | - | -4,832,000 | - | - |
| Change in fair value of warrants - qcls | 6,050,000 | - | - | - |
| Gain on legal settlement re-fair value of warrants | 0 | 106,000 | - | - |
| Gain on related party investment - qcls | 2,089,000 | - | - | - |
| Issuance costs series c convertible preferred stock and warrants | -1,234,553 | - | - | - |
| Loss on issuance of series c convertible preferred stock | -215,000 | - | - | - |
| Unrealized loss on marketable securities | -60,663 | -104,463 | - | - |
| Other expense | -95 | -121 | -1,062 | -190 |
| Total other income and (expense), net | -6,041,924 | -7,511,791 | -363,500 | 24,690,242 |
| Net income (loss) | -7,417,975 | -8,360,096 | -1,469,560 | 23,421,355 |
| Preferred stock dividends | 96,639 | 0 | 443,958 | 685,801 |
| Preferred stock accretion | 901,996 | 0 | 1,045,357 | 2,148,047 |
| Net income (loss) attributable to common stockholders | -8,416,610 | -8,360,096 | -2,958,875 | 20,587,507 |
| Basic income (loss) per share attributable to common stockholders | -1.24 | -1.23 | -0.39 | 1.9 |
| Diluted income (loss) per share attributable to common stockholders | -1.24 | -1.23 | -0.39 | 1.9 |
| Weighted average shares outstanding basic | 6,795,779 | 6,795,779 | 7,637,034 | 7,866,387 |
| Weighted average shares outstanding diluted | 6,795,779 | 6,795,779 | 7,637,034 | 7,866,387 |
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)